Alpha Tau Medical Ltd (DRTS) News

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW), ("Alpha Tau" or...

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

JERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ:...

Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium

JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to...

Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference

JERUSALEM, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Alpha Tau Treats First Patient with Recurrent Lung Cancer

JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

JERUSALEM, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Con

JERUSALEM, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat...